Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
10 May 2023 Announcement of General Shareholders’ Meeting ROVI releases the information related to its General Shareholders Meeting Download
10 Apr 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the first quarter of 2023 Download
21 Feb 2023 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors Download
21 Feb 2023 Annual Corporate Governance Report ROVI releases the 2022 Annual Corporate Governance Report Download
16 Feb 2023 On business and financial situation The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages